Study #2025-0062
A phase 2 study to evaluate the efficacy and safety of Selinexor monotherapy in subjects with JAK inhibitor-naive myelofibrosis and moderate thrombocytopenia
MD Anderson Study Status
Enrolling
Treatment Agent
Selinexor 60 mg, Ruxolitinib, Pacritinib, Momelotinib, Selinexor 40 mg
Description
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Study phase:
Phase II
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.